OSCR
Oscar Health, Inc.
OSCR has the edge over XGN overall, supported by stronger fundamentals and lower modeled downside.
XGN
Exagen Inc.
XGN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XGN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XGN PE Valuation
XGN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect XGN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XGN on earnings quality, reporting a profit while its opponent remains loss making.
XGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.76 | +$0.16 |
| Q2 2026 | -$0.82 | +$0.07 |
| Q1 2026 | -$0.90 | -$0.06 |
| Q4 2025 | -$0.93 | -$0.10 |
| Q3 2025 | -$0.92 | +$0.02 |
| Q2 2025 | -$0.89 | +$0.08 |
| Q1 2025 | -$0.84 | +$0.25 |
| Q4 2024 | -$0.83 | +$0.51 |
XGN is still losing money, but far less than before: $0.76 per share over the past year, against $2.77 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over XGN on profitability, with a higher operating margin.
XGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.4M | +6.8% |
| Q2 2026 | $19.9M | +16% |
| Q1 2026 | $17.3M | +12% |
| Q4 2025 | $16.6M | +22% |
| Q3 2025 | $17.2M | +38% |
| Q2 2025 | $17.2M | +14% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
XGN's revenue has grown year over year for seven quarters in a row: $18M last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | -5.9 points |
| Q2 2026 | -8.6% | +6.6 points |
| Q1 2026 | -20% | +2 points |
| Q4 2025 | -30% | -5.1 points |
| Q3 2025 | -18% | +19 points |
| Q2 2025 | -15% | +1.9 points |
| Q1 2025 | -22% | -0.9 points |
| Q4 2024 | -25% | +13 points |
XGN's operating margin was −24% last quarter, down 5.9 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
XGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -204% |
| Q2 2026 | $3.4M | +$6.5M |
| Q1 2026 | -$10.6M | +$139K |
| Q4 2025 | -$3.1M | -1509% |
| Q3 2025 | $2.7M | +$5M |
| Q2 2025 | -$3.1M | -$532K |
| Q1 2025 | -$10.8M | -$1.7M |
| Q4 2024 | $217K | -97% |
XGN has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +685K shares |
| 1 year | +8.3% | +1.9M shares |
| 3 years | +40% | +7.2M shares |
| 5 years | +47% | +7.9M shares |
| Available history | +97% | +12.3M shares |
XGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XGN Net Leverage
XGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 38.4 | Neutral |
XGN's weekly RSI is 40 (neutral) and its Stochastic is 38 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XGN PE vs Healthcare Sector
XGN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XGN on trend strength, trading above more of its moving averages.
XGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.39 | 40% below |
| 20 week MA | $6.68 | 34% below |
| 50 week MA | $5.21 | 15% below |
| 100 week MA | $6.05 | 27% below |
| 200 week MA | $4.23 | 4.3% above |
XGN has fallen below most of its moving averages, though it's still 4.3% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XGN on returns for 2026, with the stronger performance.
XGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.7 | $12.3 | -52% |
| 2021 | $12.3 | $11.0 | -10% |
| 2022 | $11.0 | $2.45 | -78% |
| 2023 | $2.45 | $1.99 | -19% |
| 2024 | $1.99 | $4.71 | +137% |
| 2025 | $4.71 | $6.13 | +30% |
| 2026 YTD | $6.13 | $4.41 | -28% |
XGN's yearly returns have swung widely, from +137% in 2024 to −78% in 2022. It's down 28% so far in 2026.